Biopharma-asia
Large-scale Production of Biologics is susceptible to microbial contamination because many manufacturing steps occur under non-sterile conditions in aqueous systems at ambient temperature or 2-8 °C under substantially neutral pH conditions. Regardless of where in the Drug Substance (DS) manufacture (manufacture of the Active Pharmaceutical Ingredient), or Drug Product (DP) manufacture (manufacture of the Final Drug, e.g. formulated mAbs filled in vials or syringes) they occur, microbial contaminations can have a significant impact on product quality and patient safety.
Watch Now
europeanpharmaceuticalreview
This webinar is designed to help companies understand the application and benefit of ozone technology in ultrapure water systems and how ozone solutions can improve water system performance, uptime and product quality in pharmaceutical manufacturing applications.
Watch Now
business-review-webinars
Sterile filtration has been a cornerstone of bioprocessing for over 60 years and as the industry continues its change from stainless steel to single-use, filtration has also evolved, moving from cartridge to capsule format with several membrane types to choose from. This webinar aims to provide an overview of filtration in bioprocessing addressing key considerations when developing a biopharmaceutical manufacturing process.
Watch Now
Throughout the pharma industry, real-world evidence (RWE) is leveraged across organizations for key decision-making within a therapy’s life cycle — from R&D to new US Food and Drug Administration (FDA) drug submissions to commercial strategy operations.
Watch Now